TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation
Brief Summary: The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.


Options:
A: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
B: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
C: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open Label Clinical Trial of Maternal Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Maximal Reduction of Mother-to-child HIV Transmission in Resource-limited Settings Among Breastfeeding Populations
Brief Summary: The purpose of the study is to demonstrate that a regimen using highly active antiretroviral therapy (HAART) to maximally suppress maternal viral load in the late antenatal period and during the first six months of lactation is safe, effective and can be implemented in resource poor settings in order to reduce the risk of HIV transmission to the infant.


Options:
A: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combined short-course zidovudine/nevirapine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: HAART | Intervention Type: DRUG; Name: Combined short-course zidovudine/nevirapine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: HAART; Assigned to Arm(s): A
B: Arm Label: 2A; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 2A | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2B
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine and mulitvitamins | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine and mulitvitamins | Intervention Type: DRUG; Name: Nevirapine and mulitvitamins; Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: Zidovudine/Lamivudine and either Nevirapine or Nelfinavir; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding for 6 months postpartum; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention for Seropositive Injection Drug Users - Research and Evaluation (INSPIRE)
Brief Summary: The purpose of this study is to test whether a ten-session behavioral intervention for HIV-infected injection drug users is effective in reducing sex and injection risk behaviors that put others at risk for HIV infection, increasing access to or utilization of HIV primary health care, and increasing adherence to HIV medications.


Options:
A: Intervention Type: DRUG; Name: carvedilol plus nurse management; Assigned to Arm(s): N/A
B: Arm Label: Health coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health coaching | Arm Label: Health coaching plus home-titration; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching plus home titration | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching plus home titration; Assigned to Arm(s): Health coaching plus home-titration
C: Intervention Type: BEHAVIORAL; Name: Peer Mentoring Intervention; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: carvedilol; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD)
Brief Summary: Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this 56 day study is to learn the safety and effectiveness of Corlux in patients who have been diagnosed with psychotic major depression (PMD).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: olanzapine/sertraline combination; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Sertraline | Arm Label: olanzapine plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olanzapine, Other: placebo | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): olanzapine plus placebo, olanzapine/sertraline combination | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): olanzapine/sertraline combination | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): olanzapine plus placebo
C: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matching placebo
D: Arm Label: mifepristone 300 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: mifepristone matched placebo | Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 600 mg | Arm Label: mifepristone 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 1200 mg | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): mifepristone 300 mg | Intervention Type: DRUG; Name: mifepristone matched placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: mifepristone 600 mg; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: mifepristone 1200 mg; Assigned to Arm(s): mifepristone 1200 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase
Brief Summary: The purpose of this study is to compare the therapeutic combination of I.V. eflornithine + oral nifurtimox to the standard IV eflornithine regimen in terms of therapeutic efficacy and clinical safety, in patients suffering from Trypanosoma brucei gambiense (Tbg) human African trypanosomiasis (HAT) in the meningoencephalitic phase.


Options:
A: Intervention Type: DRUG; Name: Eflornithine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nifurtimox; Assigned to Arm(s): N/A
B: Arm Label: NECT (Nifurtimox Eflornithine Combination Therapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifurtimox, Drug: Eflornithine | Arm Label: Fexinidazole; Type: EXPERIMENTAL; Interventions: Drug: Fexinidazole | Intervention Type: DRUG; Name: Fexinidazole; Assigned to Arm(s): Fexinidazole | Intervention Type: DRUG; Name: Nifurtimox; Assigned to Arm(s): NECT (Nifurtimox Eflornithine Combination Therapy) | Intervention Type: DRUG; Name: Eflornithine; Assigned to Arm(s): NECT (Nifurtimox Eflornithine Combination Therapy)
C: Intervention Type: DRUG; Name: Nifurtimox-Eflronithine Combination Treatment (NECT); Assigned to Arm(s): N/A
D: Arm Label: Fexinidazole; Type: EXPERIMENTAL; Interventions: Drug: Fexinidazole | Intervention Type: DRUG; Name: Fexinidazole; Assigned to Arm(s): Fexinidazole

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial
Brief Summary: In areas of stable transmission, pregnant women, especially during the first and second pregnancies, have an increased susceptibility to Plasmodium falciparum malaria, malaria-related anaemia and an increased risk of having low birthweight babies. Intermittent Preventive Treatment in pregnancy(IPTp) with sulphadoxine-pyrimethamine has been shown to be effective in reducing the effects of malaria in pregnancy. This has mainly been in areas of perennial transmission and there is a need to study this effect in intense seasonal transmission settings. The emergence and spread of resistance to SP is likely to undermine its useful lifespan and it is important that other antimalarials that are safe and effective are identified for use in IPTp. The options are however limited. Amodiaquine has been shown to be effective in treatment of clinical cases of malaria, even in areas where chloroquine resistance is prevalent, and its combination with SP has been associated with favourable results. Both are affordable. However, there is limited data on their use in pregnancy. This study aims to assess the efficacy of SP in an area of intense seasonal transmission, and evaluate the safety and efficacy of amodiaquine and a combination of sulphadoxine-pyrimethamine and amodiaquine as possible alternatives to SP for use as IPTp.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Insecticide-treated mosquito bed net | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine, Device: Insecticide-treated mosquito bed net | Intervention Type: DRUG; Name: Intermittent preventive treatment:sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 3 | Intervention Type: DEVICE; Name: Insecticide-treated mosquito bed net; Assigned to Arm(s): 2, 3
D: Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine, amodiaquine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Non-Severe Malaria at Different Transmission Intensities of Plasmodium Falciparum in Tanzania
Brief Summary: There is clear evidence diagnosis of malaria in much of Africa is sub-optimal and this has a negative impact on patient care. Many of those treated for malaria do not have it. Rapid diagnostic tests (RDTs) are dipsticks which diagnose malaria rapidly and accurately. The main objective of this trial is to determine by means of a randomised trial the impact of introducing RDTs into a standard outpatient setting in Tanzania has on the appropriate prescription of antimalarials. Other objectives are:

1. To compare at high, moderate and low P.falciparum transmission intensity the sensitivity and specificity of malaria diagnosis using hospital slide results and RDTs, using research quality slides as the reference.
2. To estimate the specificity of clinical diagnosis of malaria at high, moderate and low transmission intensity of P. falciparum.
3. To compare the proportion of cases reported as slide-negative who are treated for malaria with the proportion of RDT-negative cases treated for malaria.
4. To evaluate the cost effectiveness of introducing RDTs compared to current diagnostic practice in facilities with microscopic diagnosis of malaria at different levels of transmission of P.falciparum.


Options:
A: Intervention Type: DEVICE; Name: Rapid Diagnostic Test for P. falciparum malaria; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Rapid diagnostic test for malaria | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test for malaria | Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): 1, 2
C: Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Microscopy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clinical diagnosis for malaria | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Rapid diagnostic test | Intervention Type: PROCEDURE; Name: Rapid diagnostic test; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Microscopy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Clinical diagnosis for malaria; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Non-Severe Malaria at Different Transmission Intensities of Plasmodium Falciparum in Tanzania
Brief Summary: There is clear evidence diagnosis of malaria in much of Africa is sub-optimal and this has a negative impact on patient care. Many of those treated for malaria do not have it. Rapid diagnostic tests (RDTs) are dipsticks which diagnose malaria rapidly and accurately. The main objective of this trial is to determine by means of a randomised trial the impact of introducing RDTs into a standard outpatient setting in Tanzania has on the appropriate prescription of antimalarials. Other objectives are:

1. To compare at high, moderate and low P.falciparum transmission intensity the sensitivity and specificity of malaria diagnosis using hospital slide results and RDTs, using research quality slides as the reference.
2. To estimate the specificity of clinical diagnosis of malaria at high, moderate and low transmission intensity of P. falciparum.
3. To compare the proportion of cases reported as slide-negative who are treated for malaria with the proportion of RDT-negative cases treated for malaria.
4. To evaluate the cost effectiveness of introducing RDTs compared to current diagnostic practice in facilities with microscopic diagnosis of malaria at different levels of transmission of P.falciparum.


Options:
A: Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): N/A
B: Arm Label: RDT+ACT group; Type: EXPERIMENTAL; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Arm Label: Clinical judgement+ACT group; Type: ACTIVE_COMPARATOR; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Intervention Type: DEVICE; Name: RDT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group | Intervention Type: OTHER; Name: Clinical Judgement as basis for treatment of malaria with ACT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Clinical algorithm and microscopy diagnosis of malaria | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Clinical algorithm and microscopy diagnosis of malaria | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Clinical algorithm and microscopy diagnosis of malaria; Assigned to Arm(s): 1, 2
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Microscopy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clinical diagnosis for malaria | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Rapid diagnostic test | Intervention Type: PROCEDURE; Name: Rapid diagnostic test; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Microscopy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Clinical diagnosis for malaria; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Post Traumatic Stress Disorder by Early Treatment
Brief Summary: To prospectively evaluate the effect of early treatment (cognitive therapy (CT), cognitive-behavioral therapy (CBT) and escitalopram (SSRI) in preventing the occurrence of post-traumatic stress disorder in recent survivors of traumatic events.


Options:
A: Arm Label: Prolonged Exposure (CBT); Type: EXPERIMENTAL; Interventions: Procedure: Cognitive Behavioral Therapy | Arm Label: Cognitive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive Therapy | Arm Label: SSRI (escitalopram); Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Waiting List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Prolonged Exposure (CBT) | Intervention Type: PROCEDURE; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): SSRI (escitalopram) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A
C: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
D: Arm Label: Ketamine arm; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Post Traumatic Stress Disorder by Early Treatment
Brief Summary: To prospectively evaluate the effect of early treatment (cognitive therapy (CT), cognitive-behavioral therapy (CBT) and escitalopram (SSRI) in preventing the occurrence of post-traumatic stress disorder in recent survivors of traumatic events.


Options:
A: Arm Label: Psycho-educational intervention; Type: EXPERIMENTAL; Interventions: Other: Psycho-education | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Psycho-education; Assigned to Arm(s): Psycho-educational intervention
B: Arm Label: Cognitive Behavior Therapy - males; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Cognitive Behavior Therapy - females; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Usual Cardiac Care - Males; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Arm Label: Usual Cardiac Care - females; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Intervention Type: BEHAVIORAL; Name: Cognitive Behaviour Therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy - females, Cognitive Behavior Therapy - males | Intervention Type: OTHER; Name: Usual Cardiac Care (UCC); Assigned to Arm(s): Usual Cardiac Care - Males, Usual Cardiac Care - females
C: Arm Label: Prolonged Exposure (CBT); Type: EXPERIMENTAL; Interventions: Procedure: Cognitive Behavioral Therapy | Arm Label: Cognitive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive Therapy | Arm Label: SSRI (escitalopram); Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Waiting List; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Prolonged Exposure (CBT) | Intervention Type: PROCEDURE; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): SSRI (escitalopram) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure (PE) Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure (PE) Therapy; Assigned to Arm(s): 2

Answer: C